Neurogene Inc.
NasdaqGM NGNE
Neurogene Inc. Price to Sales Ratio (P/S) on January 14, 2025: 287.30
Neurogene Inc. Price to Sales Ratio (P/S) is 287.30 on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
-
Neurogene Inc. 52-week high Price to Sales Ratio (P/S) is 1,147.90 on November 11, 2024, which is 299.55% above the current Price to Sales Ratio (P/S).
-
Neurogene Inc. 52-week low Price to Sales Ratio (P/S) is 246.19 on November 20, 2024, which is -14.31% below the current Price to Sales Ratio (P/S).
-
Neurogene Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 594.17.
Key data
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Market news
Loading...
NasdaqGM: NGNE
| CEO | Dr. Rachel L. McMinn Ph.D. |
| IPO Date | March 7, 2014 |
| Location | United States |
| Headquarters | 535 W 24th Street |
| Employees | 91 |
| Sector | Health Care |
| Industries | |
Description
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email